- Home
- CII vs ARVN Comparison
CII vs ARVN Comparison
Compare CII & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CII | ARVN |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 916.6M | 781.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CII | ARVN |
|---|---|---|
| Price | $21.83 | $13.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $15.71 |
| AVG Volume (30 Days) | 92.0K | ★ 733.1K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 6.17% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.20 | $5.90 |
| 52 Week High | $26.17 | $18.45 |
Technical Indicators
Market Signals| Indicator | CII | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 33.91 | 57.02 |
| Support Level | $21.53 | $11.07 |
| Resistance Level | $22.30 | $13.97 |
| Average True Range (ATR) | 0.27 | 0.76 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 2.15 | 83.05 |
Price Performance
Historical ComparisonAbout CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.